| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cda63a5c3d6287c3bffdd696f8c39ca2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d6ed4f4345391843b1d41f9491fd3a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12cf23f68414dde562933b1c79207904
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e04a9c30b01a6909696dc92e883f241c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-462 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| filingDate |
2010-07-02^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-11-11^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e032043dd72462f713c56fd18d7221f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_094b88ab947adcbf01c27177354d5935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0062c1f37a2b6067aceb82acf10af791 |
| publicationDate |
2014-11-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8883981-B2 |
| titleOfInvention |
Recombinant antibody composition |
| abstract |
The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient. |
| priorityDate |
2005-07-22^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |